Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 15 2022 - 7:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16
OR 15d-16 UNDER
THE SECURITIES EXCHANGE
ACT OF 1934
For the month of November 2022
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On November 15, 2022, CollPlant Biotechnologies
Ltd. issued a press release entitled “CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based
3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis.” A copy of this press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD. |
|
|
|
Date: November 15, 2022 |
By: |
/s/ ERAN ROTEM |
|
|
Name: |
Eran Rotem |
|
|
Title: |
Deputy CEO and Chief Financial Officer |
2
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024